OPEN END TURBO PUT-OPTIONSSCHEIN MIT SL - ASTRAZENECA | Delayed Deutsche Boerse AG 12:02:15 2024-05-21 EDT | ||
| 3.35 EUR | -10.67% |
|
| Current month | -2.34% | ||
| 1 month | -24.70% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ASTRAZENECA PLC
Latest news about ASTRAZENECA PLC
| Date | Price | Change |
|---|---|---|
| 24-05-21 | 3.35 | -10.67% |
| 24-05-20 | 3.75 | +0.54% |
| 24-05-17 | 3.73 | +1.36% |
| 24-05-16 | 3.68 | +0.82% |
| 24-05-15 | 3.65 | +5.80% |
Delayed Quote Deutsche Boerse AG
Last update May 21, 2024 at 12:02 pm
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | ASTRAZENECA PLC |
| Issuer | 
Société Générale
|
| WKN | SN5D0X |
| ISIN | DE000SN5D0X3 |
| Date issued | 2022-07-12 |
| Strike | 15,312 p |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 5.58 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 7.08 € |
|---|---|
| Lowest since issue | 3.35 € |
Company Profile
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
-
Consensus: AstraZeneca PLC
Sell
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
153.7
USD
Average target price
168.1
USD
Spread / Average Target
+9.41%
- Stock Market
- Certificates
- Certificat
